Swedish Orphan Biovitrum AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOVF research report →
Companywww.sobi.com
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact.
- CEO
- Guido Oelkers
- IPO
- 2021
- Employees
- 1,895
- HQ
- Solna, SE
Price Chart
Valuation
- Market Cap
- $16.42B
- P/E
- 163.83
- P/S
- 5.21
- P/B
- 3.74
- EV/EBITDA
- 14.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 44.17%
- Op Margin
- 29.56%
- Net Margin
- 3.18%
- ROE
- 2.41%
- ROIC
- 12.10%
Growth & Income
- Revenue
- $28.17B · 8.22%
- Net Income
- $476.80M · -87.73%
- EPS
- $1.39 · -87.77%
- Op Income
- $8.03B
- FCF YoY
- 93.99%
Performance & Tape
- 52W High
- $47.48
- 52W Low
- $27.06
- 50D MA
- $42.54
- 200D MA
- $36.06
- Beta
- 0.26
- Avg Volume
- 13
Get TickerSpark's AI analysis on BIOVF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BIOVF Coverage
We haven't published any research on BIOVF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BIOVF Report →